

# A Rare Retroperitoneal Mass Simulating A Complicated Diverticulitis

Juan Adams-Chahin, MD (1); Paloma Velasco-Corrado, MD (1); Gabriela Negron-Ocasio, MD (1); Juan Santiago-Gonzalez, MD (1); Marcel Mesa, MD (1); Jorge Barletta-Farias, MD (1); Enrique Leal-Alvarez (1).

Department of Internal Medicine, University of Puerto Rico School of Medicine (1)



## Introduction

- Extra-gastrointestinal stromal tumors (EGISTs) are a group of rare neoplasm that arises from cells outside the gastrointestinal (GI) tract.
- Occurs in <5% of all GISTs involving the retroperitoneum, mesentery, or omentum with a more aggressive behavior.
  - GISTs represent 1-2% of all primary GI cancer
- EGISTs typically present as large intra-abdominal masses with unspecific symptoms.
- We report a case of an EGIST mimicking diverticulitis with contained perforation.

## Clinical Case

- 50-year-old male inmate with no medical history presents to the ED due to worsening abdominal pain that began 5 days prior to admission.
- Symptoms began suddenly associated to unquantified episodes of non-bloody, non-watery diarrhea, vomiting of gastric content and subjective fever.
- Physical exam with signs of dehydration, a distended abdomen with hyperactive bowel sounds, and a non-mobile large mass on the left lower quadrant with tenderness to light palpation and guarding.
- Laboratories were remarkable for neutrophilic leukocytosis, thrombocytosis, and elevated inflammatory markers.



- Abdomino-pelvic CT: Large left heterogeneously enhancing retroperitoneal mass with central necrosis measuring 18.6 cm AP x 18.4 cm transverse x 25.3 cm CC.
- Core-needle biopsy → high-risk GIST with positive immunohistochemistry for
  - C-KIT, CD34, CD56, Actin & Desmin
  - Very high mitotic index (45 mitosis/25 HPF).
- Surgery was deferred due to large size of mass and closure to adjacent structures.
- Neoadjuvant therapy with Imatinib was started but the patient was lost to follow up upon discharge.

## Discussion

- This case describes a rare presentation of EGIST emerging from the retroperitoneum with a positive immunohistochemistry for desmin (1-2%) and manifesting as a complicated diverticulitis.
- Although there is limited data, EGISTs are known to relapse more frequently than GISTs thus the importance of implementing gene sequencing for developing new directed therapy.
- Furthermore, because EGISTs are found outside the GI system, symptoms only appear when the tumor has progressed to an advanced stage giving it a worse prognosis.

## Conclusions

- EGISTs should be in the differential diagnosis of patients presenting with an abdominal mass.
- More research is needed to better understand the behavior, prognosis, and treatment options of these tumors.

## References

- T.M. Parab, M.J. DeRogatis, A.M. Boaz, S.A. Grasso, P.S. Issack, D.A. Duarte, et al. *Gastrointestinal stromal tumors: a comprehensive review*. J. Gastrointest. Oncol., 10 (2019), pp. 144-154, 10.21037/jgo.2018.08.20.
- J.H. Yi, B.B. Park, J.H. Kang, I.G. Hwang, D.B. Shin, S.J. Sym, et al. *Retrospective analysis of extra-gastrointestinal stromal tumors*. World J. Gastroenterol., 21 (6) (2015), pp. 1845-1850, 10.3748/wjg.v21.i6.1845.
- Soreide K.; Sandvik O. M.; Soreide J. A.; et al. *Global epidemiology of gastrointestinal stromal tumors (GIST): A systematic review of population-based cohort studies*. Cancer Epidemiol 2016; 40:39.